This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leslie, H. Articles by Atkinson, A. B. Search for Related Content PubMed PubMed Citation Articles by Leslie, H. Articles by Atkinson, A. B.

Laboratory and Clinical Experience in 55 Patients with Macroprolactinemia Identified by a Simple Polyethylene Glycol Precipitation Method

Sir George E. Clark Metabolic Unit (C.H.C., P.M.B., D.R.H., D.R.M., A.B.A.), Regional Endocrine Laboratory (H.L., B.S.), and Department of Radiology (P.K.E.), Royal Victoria Hospital, Belfast, United Kingdom BT12 6BA

Address all correspondence and requests for reprints to: Prof. A. B. Atkinson, Sir George E. Clark Metabolic Unit, Royal Victoria Hospital, Belfast, United Kingdom BT12 6BA. E-mail: abatkinson{at}royalhospitals.n-i.nhs.uk

Abstract

PRL exists in different forms in human serum. The predominant form is little PRL (molecular mass 23 kDa) with smaller amounts of big PRL (molecular mass 50–60 kDa) and at times big big or macroprolactin (molecular mass 150–170 kDa). The frequency and clinical consequences of macroprolactinemia have not been clearly established, mainly because of difficulty in identifying these patients biochemically. This previously required the use of gel filtration chromatography, which could not be used routinely. Recently, a screening test using polyethylene glycol (PEG) has been used to identify macroprolactin in serum. Consequently, this study was designed to examine the use of PEG precipitation in the identification of patients with a predominance of macroprolactin and to establish the clinical characteristics of such a cohort.

Over 12 months, 18,258 requests for serum PRL were received and of these 1225 patients had a serum PRL more than 700 mU/L. A total of 322 of these patients (26%) had a percentage recovery after PEG precipitation of less than 40%, thus indicating the presence of a predominance of macroprolactin.

Fifty-five of these patients were referred for detailed clinical assessment. Symptoms typical of hyperprolactinemia were not common in this cohort. None had sustained amenorrhea and eight have had oligomenorrhea at age less than 40 yr. One had galactorrhea. All had pituitary imaging, and four had a microadenoma with none having a macroadenoma.

PEG precipitation allows easy identification of macroprolactin in routine clinical practice. As the clinical consequences of this entity at this stage seem relatively benign, referral and intensive investigation of these patients may not be necessary. However, follow-up of a large cohort is required to ensure that the long-term outlook is likewise benign. This would have important implications for both patients and healthcare systems.

This article has been cited by other articles:

				L. Beltran, M. N. Fahie-Wilson, T. J. McKenna, L. Kavanagh, and T. P. Smith Serum Total Prolactin and Monomeric Prolactin Reference Intervals Determined by Precipitation with Polyethylene Glycol: Evaluation and Validation on Common ImmunoAssay Platforms Clin. Chem., October 1, 2008; 54(10): 1673 - 1681. [Abstract] [Full Text] [PDF]

				N Hattori, Y Nakayama, K Kitagawa, T Ishihara, Y Saiki, and C Inagaki Anti-prolactin (PRL) autoantibody-binding sites (epitopes) on PRL molecule in macroprolactinemia. J. Endocrinol., August 1, 2006; 190(2): 287 - 293. [Abstract] [Full Text] [PDF]

				A. Glezer, C. R. J. Soares, J. G. Vieira, D. Giannella-Neto, M. T. C. P. Ribela, V. Goffin, and M. D. Bronstein Human Macroprolactin Displays Low Biological Activity via Its Homologous Receptor in a New Sensitive Bioassay J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1048 - 1055. [Abstract] [Full Text] [PDF]

				J. Gibney, T. P. Smith, and T. J. McKenna The Impact on Clinical Practice of Routine Screening for Macroprolactin J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3927 - 3932. [Abstract] [Full Text] [PDF]

				N. Hattori, K. Ikekubo, Y. Nakaya, K. Kitagawa, and C. Inagaki Immunoglobulin G Subclasses and Prolactin (PRL) Isoforms in Macroprolactinemia Due to Anti-PRL Autoantibodies J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3036 - 3044. [Abstract] [Full Text] [PDF]

				A. M. Suliman, T. P. Smith, J. Gibney, and T. J. McKenna Frequent Misdiagnosis and Mismanagement of Hyperprolactinemic Patients before the Introduction of Macroprolactin Screening: Application of a New Strict Laboratory Definition of Macroprolactinemia Clin. Chem., September 1, 2003; 49(9): 1504 - 1509. [Abstract] [Full Text] [PDF]

				C. Mounier, J. Trouillas, B. Claustrat, R. Duthel, and B. Estour Macroprolactinaemia associated with prolactin adenoma Hum. Reprod., April 1, 2003; 18(4): 853 - 857. [Abstract] [Full Text] [PDF]

				C Williams, T Giannopoulos, and E A Sherriff Best Practice No 170: Investigation of infertility with the emphasis on laboratory testing and with reference to radiological imaging J. Clin. Pathol., April 1, 2003; 56(4): 261 - 267. [Abstract] [Full Text] [PDF]

				J. A. Schlechte The Macroprolactin Problem J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5408 - 5409. [Full Text] [PDF]

				C. Hekim, H. Alfthan, J. T. Leinonen, and U.-H. Stenman Effect of Incubation Time on Recognition of Various Forms of Prolactin in Serum by the DELFIA Assay Clin. Chem., December 1, 2002; 48(12): 2253 - 2256. [Full Text] [PDF]

				W. Jeske, W. Zgliczynski, and P. Zdunowski Laboratory and Clinical Experience in 55 Patients with Macroprolactinemia Identified by a Simple Polyethylene Glycol Precipitation Method J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1909 - 1910. [Full Text] [PDF]